Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Chlorothiazide

FDA-approved product (suspension, oral), marketed as Chlorothiazide, Diuril, Chlorothiazide Sodium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Chlorothiazide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Chronic kidney disease
  • Congestive heart failure
  • Edema
  • Glomerulonephritis
  • Heart failure
  • Hypertension
  • Nephrotic syndrome
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Thiazides, plain; Thiazides, combinations with psycholeptics and/or analgesics
FDA pharmacologic class
Thiazide Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis68.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Chlorothiazide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Chlorothiazide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients

    NCT02172586 · start 2000-01

    Registered record
    Registry ID
    NCT02172586
    Conditions
    Hypertension
    Interventions
    Telmisartan; Losartan; Hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-01
    Completion
    Not recorded
    Enrolment
    363

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionTelmisartan; Losartan; Hydrochlorothiazide
    PhasePhase 4
    Registry statusCompleted

  • A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension

    NCT03276598 · start 1999-11-25

    Registered record
    Registry ID
    NCT03276598
    Conditions
    Hypertension; Pharmacogenetics
    Interventions
    Amlodipine; Bisoprolol; Hydrochlorothiazide; Losartan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1999-11-25
    Completion
    2004-04-01
    Enrolment
    233

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Pharmacogenetics
    InterventionAmlodipine; Bisoprolol; Hydrochlorothiazide; Losartan +1 more
    PhasePhase 4
    Registry statusCompleted

  • Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment

    NCT00813722 · start 1999-03

    Registered record
    Registry ID
    NCT00813722
    Conditions
    Blood Pressure
    Interventions
    phone call; amlodipine (calcium chanel blocker) and losartan (at1 antagonist); atenolol (beta blocker) and hydrochlorothiazide (diuretic)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    1999-03
    Completion
    2009-06
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlood Pressure
    Interventionphone call; amlodipine (calcium chanel blocker) and losartan (at1 antagonist); atenolol (beta blocker) and hydrochlorothiazide (diuretic)
    PhasePhase 4
    Registry statusUnknown

  • Treatment of Hypertension

    NCT00000484 · start 1966-04

    Registered record
    Registry ID
    NCT00000484
    Conditions
    Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
    Interventions
    chlorothiazide; Rauwolfia alkaloids
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1966-04
    Completion
    1979-01
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
    Interventionchlorothiazide; Rauwolfia alkaloids
    PhasePhase 3
    Registry statusCompleted

  • Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fed Conditions

    NCT01218724

    Registered record
    Registry ID
    NCT01218724
    Conditions
    Healthy
    Interventions
    Losartan Potassium and Hydrochlorothiazide Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLosartan Potassium and Hydrochlorothiazide Tablets
    PhasePhase 1
    Registry statusCompleted